Focused On-demand Library for Mitogen-activated protein kinase kinase kinase 19

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q56UN5

UPID:

M3K19_HUMAN

Alternative names:

Regulated in COPD, protein kinase; SPS1/STE20-related protein kinase YSK4

Alternative UPACC:

Q56UN5; B2RP57; B7ZMH9; E2QRE3; Q56UN1; Q56UN2; Q56UN3; Q56UN4; Q8N4E9; Q9H5T2

Background:

Mitogen-activated protein kinase kinase kinase 19, also known by its alternative names Regulated in COPD, protein kinase and SPS1/STE20-related protein kinase YSK4, plays a crucial role in cellular signaling pathways. This kinase is part of a larger family of MAP kinases, which are involved in various cellular processes such as proliferation, differentiation, and stress responses.

Therapeutic significance:

Understanding the role of Mitogen-activated protein kinase kinase kinase 19 could open doors to potential therapeutic strategies. Its involvement in key signaling pathways suggests its potential as a target in treating diseases where these pathways are dysregulated.